内科学
甘油三酯
脂联素
内分泌学
血脂异常
虾青素
高脂血症
医学
安慰剂
胆固醇
体质指数
糖尿病
代谢综合征
胰岛素抵抗
化学
生物化学
替代医学
病理
类胡萝卜素
作者
Hiroshi Yoshida,Hidekatsu Yanai,Kimihiro Ito,Yoshiharu Tomono,Takashi Kobayashi,Hiroki Tsukahara,Norio Tada
出处
期刊:Atherosclerosis
[Elsevier]
日期:2010-04-01
卷期号:209 (2): 520-523
被引量:203
标识
DOI:10.1016/j.atherosclerosis.2009.10.012
摘要
Background Astaxanthin has been reported to improve dyslipidemia and metabolic syndrome in animals, but such effects in humans are not well known. Methods Placebo-controlled astaxanthin administration at doses of 0, 6, 12, 18 mg/day for 12 weeks was randomly allocated to 61 non-obese subjects with fasting serum triglyceride of 120–200 mg/dl and without diabetes and hypertension, aged 25–60 years. Results In before and after tests, body mass index (BMI) and LDL-cholesterol were unaffected at all doses, however, triglyceride decreased, while HDL-cholesterol increased significantly. Multiple comparison tests showed that 12 and 18 mg/day doses significantly reduced triglyceride, and 6 and 12 mg doses significantly increased HDL-cholesterol. Serum adiponectin was increased by astaxanthin (12 and 18 mg/day), and changes of adiponectin correlated positively with HDL-cholesterol changes independent of age and BMI. Conclusions This first-ever randomized, placebo-controlled human study suggests that astaxanthin consumption ameliorates triglyceride and HDL-cholesterol in correlation with increased adiponectin in humans.
科研通智能强力驱动
Strongly Powered by AbleSci AI